Skip to main content
Toggle navigation
Login
Home
iwCLL X / Twitter
Favorite
Tweet
Susan M. Schwager, BS
Research Specialist
Department of Hematology, Mayo Clinic
Poster(s):
1502 - Sequencing single novel agent-based therapy for patients with CLL: A retrospective study of patients treated with covalent Bruton Tyrosine Kinase inhibitor (cBTKi) followed by B-cell lymphoma 2 inhibitor (BCL2i) versus BCL2i followed by cBTKi